Eloxx Pharmaceuticals Inc.
ELOX | NASDAQ
$13.45
+$0.27 (+2.05%)
At close: Oct 30, 2026, 4:00 PM ET
$13.90
+$0.45 (+3.35%)
After-hours:
Oct 30, 2026, 7:30 PM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q1 2025 Mar 31, 2025 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 737K | 738K | 682K | 694K | 718K | 808K | 1.01M | 960K | 904K | 768K | 598K |
Gross Profit | n/a | n/a | n/a | -737K | -738K | -682K | -694K | -718K | -808K | -1.01M | -960K | -904K | -768K | -598K |
Operating Income | -8.25M | -3.8M | -1.22M | -19.29M | -22.79M | -28.95M | -34.42M | -40.02M | -43.12M | -45.89M | -43.35M | -37.5M | -33.55M | -28.08M |
Interest Income | 64K | 23K | 5K | 386K | 474K | 428K | 274K | 133K | 61K | 50K | 36K | 37K | 18K | 76K |
Pretax Income | -8.26M | -3.75M | -1.71M | -20.56M | -24.48M | -30.75M | -36.14M | -41.84M | -44.21M | -69.65M | -66.73M | -60.76M | -57.5M | -29.33M |
Net Income | -8.26M | -3.75M | -1.71M | -20.48M | -24.4M | -30.68M | -36.07M | -41.84M | -44.21M | -69.65M | -66.73M | -60.76M | -57.5M | -29.33M |
Selling & General & Admin | 3.75M | 2.14M | 712K | 8.18M | 8.05M | 8.95M | 10M | 10.96M | 13.64M | 18.15M | 19.49M | 18.97M | 17.13M | 14.01M |
Research & Development | 4.5M | 1.66M | 510K | 10.37M | 14M | 19.32M | 23.73M | 28.34M | 28.67M | 26.73M | 22.9M | 17.63M | 15.65M | 13.47M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 8.25M | 3.8M | 1.22M | 18.55M | 22.06M | 28.27M | 33.73M | 39.3M | 42.32M | 44.88M | 42.39M | 36.6M | 32.78M | 27.48M |
Interest Expense | 37K | 29K | 483K | 1.53M | 1.79M | 2.03M | 1.95M | 1.82M | 1.56M | 1.4M | 1.26M | 1.12M | 1.23M | 1.25M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 8.25M | 3.8M | 1.22M | 19.29M | 22.79M | 28.95M | 34.42M | 40.02M | 43.12M | 45.89M | 43.35M | 37.5M | 33.55M | 28.08M |
Income Tax Expense | n/a | n/a | n/a | -77K | -77K | -77K | -77K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.79M | 4.38M | 345.92K | 249.79K | 201.12K | 196.94K | 196.94K | 196.95K | 196.94K | 196.93K | 196.33K | 195.93K | 150.89K | 91.32K |
Shares Outstanding (Diluted) | 6.79M | 4.38M | 345.92K | 249.79K | 201.12K | 196.94K | 196.94K | 196.95K | 196.94K | 196.93K | 196.33K | 195.93K | 150.89K | 91.32K |
EPS (Basic) | -1.52 | -0.86 | -4.95 | -99.68 | -123.42 | -155.75 | -183.12 | -212.61 | -224.94 | -410.01 | -446.22 | -451.78 | -473.86 | -321.36 |
EPS (Diluted) | -1.52 | -0.86 | -4.95 | -99.68 | -123.42 | -155.75 | -183.12 | -212.61 | -224.94 | -410.01 | -446.22 | -451.78 | -473.86 | -321.36 |
EBITDA | -8.18M | -3.73M | -1.23M | -18.29M | -21.95M | -28.04M | -33.5M | -39.29M | -41.85M | -67.24M | -64.49M | -58.69M | -55.46M | -27.48M |
EBIT | -8.18M | -3.73M | -1.23M | -19.03M | -22.69M | -28.72M | -34.19M | -40.01M | -42.65M | -68.25M | -65.45M | -59.6M | -56.23M | -28.08M |
Depreciation & Amortization | n/a | n/a | n/a | 737K | 738K | 682K | 694K | 718K | 808K | 1.01M | 960K | 904K | 768K | 598K |
Add to Watchlist
Select watchlists to add or remove ELOX